#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ben Montgomery Email
Senior Director, Corporate Counsel . Surface Oncology
Cambridge, MA
Locationb**********@surfaceoncology.com
Primary EmailHow to contact Ben Montgomery
Join and see Ben's contact info for free!Current Roles
Employees:
48Revenue:
$59.4MAbout
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.Surface Oncology Address
50 Hampshire StreetCambridge, MA
United States